Artificial Pancreas: Model Predictive Control Design from Clinical Experience
Искусственная поджелудочная железа: разработка управления с прогнозирующей моделью на основе клинического опыта
2013-11-01
SCID: 54.1/sek9pc2j
Discuss with AI
Kalman filterUniversity of Virginia/Padova simulatorartificial pancreascontinuous glucose monitoringmodel predictive control
Figures from the paper
Abstract (AI)
BACKGROUND: The objective of this research is to develop a new artificial pancreas that takes into account the experience accumulated during more than 5000 h of closed-loop control in several clinical research centers. The main objective is to reduce the mean glucose value without exacerbating hypo phenomena. Controller design and in silico testing were performed on a new virtual population of the University of Virginia/Padova simulator. METHODS: A new sensor model was developed based on the Comparison of Two Artificial Pancreas Systems for Closed-Loop Blood Glucose Control versus Open-Loop Control in Patients with Type 1 Diabetes trial AP@home data. The Kalman filter incorporated in the controller has been tuned using plasma and pump insulin as well as plasma and continuous glucose monitoring measures collected in clinical research centers. New constraints describing clinical knowledge not incorporated in the simulator but very critical in real patients (e.g., pump shutoff) have been introduced. The proposed model predictive control (MPC) is characterized by a low computational burden and memory requirements, and it is ready for an embedded implementation. RESULTS: The new MPC was tested with an intensive simulation study on the University of Virginia/Padova simulator equipped with a new virtual population. It was also used in some preliminary outpatient pilot trials. The obtained results are very promising in terms of mean glucose and number of patients in the critical zone of the control variability grid analysis. CONCLUSIONS: The proposed MPC improves on the performance of a previous controller already tested in several experiments in the AP@home and JDRF projects. This algorithm complemented with a safety supervision module is a significant step toward deploying artificial pancreases into outpatient environments for extended periods of time.
Key Findings
1
A new artificial-pancreas model predictive controller was developed using experience from more than 5,000 hours of clinical closed-loop control.
2
Intensive simulator testing and preliminary outpatient pilots showed promising mean-glucose outcomes and fewer patients in the critical control-variability-grid zone, improving on a previous controller.
3
Its Kalman filter was tuned using plasma insulin, pump insulin, plasma glucose, and continuous glucose-monitoring data from clinical research centers.
4
The MPC has low computational and memory requirements, making it suitable for embedded implementation.
5
The controller aims to lower mean glucose without increasing hypoglycemic events, incorporating clinical constraints such as automatic pump shutoff.
Research Object
artificial pancreas system for closed-loop blood-glucose control in people with type 1 diabetes
Research Subject
model predictive control performance and safety, including mean-glucose reduction and prevention of hypoglycemia under clinical constraints
Publication Details
Publication Date
2013-11-01
Journal
Publisher
ISSN
Cited by
106
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai3
Model Predictive Control of Type 1 Diabetes: An in Silico Trial2007
Zone Model Predictive Control: A Strategy to Minimize Hyper- and Hypoglycemic Events2010
Hypoglycemia Prevention via Pump Attenuation and Red-Yellow-Green “Traffic” Lights Using Continuous Glucose Monitoring and Insulin Pump Data2010